BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a report issued on Friday. The firm set a “sell” rating on the medical technology company’s stock.

BIOLASE Stock Performance

NASDAQ:BIOL opened at $0.15 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.68 and a debt-to-equity ratio of 34.06. The firm has a 50-day moving average price of $0.15 and a two-hundred day moving average price of $0.83. BIOLASE has a twelve month low of $0.13 and a twelve month high of $32.09. The company has a market capitalization of $4.81 million, a P/E ratio of 0.00 and a beta of 0.67.

BIOLASE (NASDAQ:BIOL) last posted its earnings results on Thursday, March 21st. The medical technology company reported ($1.76) earnings per share for the quarter. BIOLASE had a negative net margin of 41.97% and a negative return on equity of 555.22%. The business had revenue of $13.49 million for the quarter.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.